Every 8-K that Adaptimmune Therapeutics plc American (ADAP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ADAP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ADAP filings page.
Adaptimmune Therapeutics plc received a written notice from a Nasdaq Hearings Panel on September 22, 2025 granting extra time to fix its share price listing issue. The Panel gave the company until December 1, 2025 to regain compliance with Nasdaq’s minimum bid price requirement of $1.00 per share under Listing Rule 5550(a)(2), often called the Bid Price Rule.
If Adaptimmune does not meet this minimum bid price by December 1, 2025, its American Depositary Shares will be delisted from The Nasdaq Capital Market, which could reduce trading liquidity and market visibility for shareholders.
Adaptimmune Therapeutics plc has appointed Christopher Hill as its Chief Financial Officer through a consulting arrangement. Adaptimmune Limited, a subsidiary, entered into a consulting agreement with CJH Financial Limited on September 6, 2025, under which Mr. Hill will serve as CFO effective September 10, 2025.
Mr. Hill will oversee the company’s accounting and finance functions and act as the main contact with its independent auditors for quarterly and annual SEC reports. He will serve as an independent contractor, with CJH Financial Limited paid £2,200 (approximately $2,968) per day based on approved timesheets, and he will not be eligible for bonuses or share options.
The consulting agreement can be terminated by either party after a material breach, with 30 days’ notice if curable or immediately if not curable. Mr. Hill, age 45, brings over a decade of CFO and COO experience in public and private life science and therapeutics companies, and there are no disclosed related-party transactions or family relationships tied to his appointment.
Adaptimmune Therapeutics plc disclosed a Second Variation Letter Agreement affecting the share options of Mr. Wood. Under the revised terms, registered awards will continue to vest until a Revised Termination Date in line with the Plan rules and their original vesting schedules. Mr. Wood is allowed a 12‑month period from that Revised Termination Date to exercise any Market Value Options that have vested by then. The filing states that the summary is qualified by the full agreement filed as Exhibit 10.1 to the Current Report.
Adaptimmune Therapeutics plc reports the departure of Chief Commercial Officer Cintia Piccina and outlines the terms of her separation.
On August 15, 2025, subsidiary Adaptimmune, LLC entered into a separation agreement after her employment ended on August 8, 2025 by reason of redundancy, with the agreement effective August 23, 2025. Ms. Piccina will receive a lump-sum severance of $473,800, equal to 12 months of her 2025 base salary, subject to deductions, in full satisfaction of the company’s Executive Severance Policy. Her market value options continued to vest through the separation date, and she may exercise vested options over 1,125,648 ordinary shares until January 30, 2032, with 12 months from the separation date to exercise any other market value options that vested by that date.
Adaptimmune Therapeutics plc has received a new Nasdaq warning that its American Depositary Shares risk delisting after an extended share price decline. The company had already been out of compliance with Nasdaq’s $1.00 minimum bid rule since late 2024 and was given until October 27, 2025 to regain compliance following a transfer to the Nasdaq Capital Market.
On August 14, 2025, Nasdaq informed Adaptimmune that, as of August 12, 2025, its securities had a closing bid price of $0.10 or less for ten consecutive trading days, triggering Nasdaq’s Low Priced Stocks Rule. Adaptimmune plans to request a hearing before a Nasdaq panel, which will temporarily stay any delisting action while it presents a compliance plan. The ADSs will continue trading under the symbol ADAP, but there is no assurance the panel will grant continued listing or that the company will meet the requirements.
Adaptimmune Therapeutics plc announced second-quarter financial results for the period ended June 30, 2025 and provided a corporate update. The Form 8-K furnishes the companys press release as Exhibit 99.1 and states that the furnished information is not deemed "filed" for purposes of Section 18 and is not incorporated by reference except by specific reference.
The filing does not include the financial figures or operational details; the full press release attached as Exhibit 99.1 contains the detailed results and corporate update.
Adaptimmune Therapeutics (ADAP) has agreed to sell its four autologous T-cell therapy programs—TECELRA, lete-cel, afami-cel and uza-cel—to US WorldMeds for $55 million cash at closing plus up to $30 million in regulatory and commercial milestones.
Proceeds will immediately repay the company’s outstanding Hercules Capital loan. US WorldMeds will assume selected liabilities, acquire manufacturing assets, licences and regulatory files, and offer jobs to roughly half of Adaptimmune’s staff. Adaptimmune will provide transition services through 30 June 2026.
Restructuring: Following the deal, Adaptimmune plans to cut its remaining workforce by ≈62 %, booking $7–8 million in severance costs (mainly Q3-25). Senior leaders—including the Chief Medical, Commercial, Scientific and Financial Officers—will depart in August 2025.
The transaction must close by 4 Aug 2025, subject to customary conditions and the absence of any material adverse effect.
- $5 M on FDA BLA acceptance for lete-cel
- $10 M on FDA approval for lete-cel
- Up to $5 M if TECELRA quarterly U.S. sales ≥$18 M
- $10 M if combined U.S. sales of TECELRA & lete-cel ≥$200 M